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Abstract. During surgical procedures, coagulation compli-
cations may occur. Discriminating factors are multiple and
may vary because of the anatomical regions involved and
because of preexisting diseases. The aim of this study was to
analyze changes in such hematological parameters of pa-
tients undergoing conventional abdominoplasty with stan-
dard surgical procedures under general anaesthesia.
For the study, 40 patients (20 men and 20 women) 30 to 60
years with normal coagulation assessments, no previous or
current history of hemorrhagic or thrombotic disease, and
no primary family history of such problems were selected.
All the patients underwent conventional abdominoplasty
surgical procedures.
Analysis of the results suggests that immediately after sur-
gery, in the absence of any preexisting hypo- or hyperco-
agulability state, there was no circumstantial modiﬁcation
in coagulation factors considered predictive for thrombo-
embolic risk. However, an interesting diﬀerence between
male and female patients was noted. In the male group,
there was an insigniﬁcant uniform downward trend of all
values immediately after surgery.
In conclusion, women are less hypercoagulative than men
in the postoperative period, suggesting that women have
limited protection from the development of thromboem-
bolic complications immediately after surgical procedures.
Key words: Abdominal dermolipectomy—Abdominoplas-
ty—Hypercoagulability state—Plastic surgery—Surgical
risk—Thromboembolic risk
During surgical procedures, coagulation complica-
tions may occur. Discriminating factors are multiple
and may vary because of the anatomic regions in-
volved and because of preexisting diseases (e.g., he-
patopathies, nephropathies, collagen diseases, and
hematologic disorders [7,22]. In the literature of
many branches of surgery, the reported results often
are sketchy and contrasting [13,19]. However, the
thromboembolic risk in plastic surgery is largely not
known. Clearly, such risks rise in the presence of
hypoﬁbrinolysis and hypercoagulability. In fact,
numerous studies have reported that patients need
adequate prophylaxis, and it is important to obtain
information such as prothrombin time (PT), acti-
vated partial thromboplastin time (aPTT), ﬁbrino-
gen, antithrombin III, and protein C [4,29].
Prothrombin Time Test
The PT test is used to show possible deﬁciencies,
congenital or acquired, of coagulation factors from
the extrinsic pathway (VII, X, V, prothrombin,
ﬁbrinogen) and the common pathway.
Activated Partial Thromboplastin Test
The aPTT test is used to measure the diﬀerent
coagulation factors of the intrinsic pathway (XII, XI,
IX, VIII) and the common pathway (X, V, II, I). The
test is of clinical importance because it eﬀectively
diagnoses coagulation disorders and is important for
therapeutic monitoring of thromboembolic hemor-
rhagic states. Longer PT an aPTT times indicate an
elevated hemorrhagic risk, and vice versa, a short-
ened PT or aPTT is indicative of a higher thrombo-
embolic risk [10,25].
Antithrombin III Evaluation Test
Antithrombin III (ATIII) is a plasmatic protein
synthesized by hepatocytes and endothelial cells. In
vitro ATIII activity is strengthened by heparin. In
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vivo, some proteins with an heparin-like activity (lo-
cated in the endothelial wall) are capable of
strengthening the activity of ATIII. Antithrombin III
represents one of the physiologic coagulation inhibi-
tors by deactivating serum proteases (thrombin,
aXII, aXI, aIX, aX) which have procoagulate prop-
erties. A deﬁciency in ATIII levels (associated with
hepathopathies, DIC, burns, renal dropsy) results in
a higher risk of thromboembolisms.
Protein C Evaluation Test
The inactive plasmatic form of protein C is hepati-
cally synthesized. It is activated by thrombin and then
speciﬁcally modulates the endothelial cofactor
thrombomodulin [12]. Protein C inhibits the active
forms of factors V and VIII, as well as procoagulative
platelet activity. Protein C stimulates ﬁbrinolysis. A
reduction in protein C plasma levels (e.g., in cases of
hepathopathy) may largely increase thromboembolic
risks [6,18].
The aim of this study was to analyze changes in
hematologic parameters among patients undergoing
conventional abdominoplasty using standard surgical
procedures under general anesthesia at the time of
admission and 7 days after surgery. We aimed to
underscore the inﬂuence of surgical actions on
coagulation activity by quantifying thromboembolic
risks. Abdominoplasty is commonly considered a
plastic surgery procedure with a high thromboem-
bolic risk [15,27,31].
Materials and Methods
For this study, 40 patients (20 men and 20 women
ages), 30 to 60 years, with normal coagulation
assessments, no previous or current history of hem-
orrhagic or thrombotic disease, and no primary
family history of such problems were selected (Ta-
ble 1).
All the patients underwent conventional abdom-
inoplasty surgical procedures with umbiliculus
transposition and cutaneous adipose tissue excision
ranging from 1,200 to 2,000 g. The patients were
mobilized for 24 h after surgery and discharged after
72 h with antibiotic therapy.
The patients were divided into two groups
according to gender. Blood samples for PT, aPTT,
ﬁbrinogen, ATIII, and Protein C levels were taken
from the cephalic vein 1 day before the surgical
procedure and 7 days afterward. The samples were
collected in test tubes with 3.8% sodium citrate.
Prothrombin time was measured using coagulative
and nonchromogenic methods with recombinant
partial thromboplastin reagent base (RecombiPla-
stin-Instrumentation Laboratory Company, Lexing-
ton, MA, USA) to calculate the time required for clot
formation. Thromboplastin is capable of activating
the extrinsic coagulation pathway. Thus, a deﬁciency
results in prolonged clotting times. Levels of PT are
expressed in percentage of activity (normal values,
80–120%) [4].
Activated partial thromboplastin was calculated
using coagulative methods. This test measures the
time required for clot formation when citrated plas-
ma is recalciﬁed after incubation with activated sub-
stances (phospholipid platelet-like mixture). Normal
times were 25 to 35 s.
Fibrinogen was calculated using a known concen-
tration of recombined thrombin in citrated plasma
and the time necessary for clot formation (normal
values, 200–400 mg/dl).
Protein C was calculated using chromogenic tech-
niques after activation with reptile poison derivatives
(Electrachrome Protein C-Instrumentation Labora-
tory Company, Lexington, MA, USA). The protein C
value is expressed as a percentage of activity taken
from a calibration curve with a plasma or reference
standard [5,23].
Antithrombin III was measured in the presence of
heparin. Plasma dilution was tested with a ﬁxed time
for thrombin in excess. The residual thrombin
quantity was inversely proportional to the ATIII
plasma activity. The ATIII value is expressed as a
percentage of activity taken from a calibration curve
with a plasma or reference standard (normal range,
80–120%) [14].
All the values obtained were interpreted for each
parameter, and the following statistical data were
calculated: medium, standard derivation, and signi-
ﬁcance test [28].
Presurgical Evaluations
Presurgical values allowed us to categorize a group of
patients without alterations to the assessment
parameters. Independent of gender and admission
diagnosis, individual values were normally ranged.
Notwithstanding normal data ranges, values ob-
tained from male patients at t0 were moderately
higher than those for females (Tables 2, and 3).
Postoperative Evaluations
Each patient underwent blood sampling 7 days after
the surgical procedure (t7). No patients were under-
Table 1. Age Distribution of Patients
Age (years) No. of patients %
30–41 16 40
41–50 8 20
51–60 16 40
Total 40 100
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going therapy with anticoagulants or other drugs
capable of interfering with coagulation mechanisms.
A statistical signiﬁcance test was performed for each
of the reported results (Tables 4, 5, and 6).
Discussion
A detailed analysis of coagulation parameters al-
lowed us to identify patients at high risk for throm-
bosis or hemorrhaging. Such analysis also allows for
adequate prophylaxis and therapy even for patients
with no history of elevated coagulative risks [20,29].
Silent coagulation disorders often are exposed during
surgical procedures, whereas many thromboembolic
manifestation often are not noticed clinically or sta-
tistically [20]. The incidence of profundae vein
thrombosis, together with its most common sequel,
pulmonary embolism, is elevated after surgical oper-
ations, notwithstanding variations of incidence
attributable to diverse anatomic locations of the
procedure, the type of operations performed, under-
gone and individual preexisting (individual) condi-
tions [19] (Table 7).
Several studies have demonstrated that the
thromboembolic risk for the general population
exponentially increases with age [17,24], but more
precisely, such risk increases when risk factors are
present or after particular surgical procedures (Ta-
ble 8) [30].
In our patient group, the analysis of coagulation
parameters allowed us to identify patients with
thrombotic and hemorrhagic risks, independently of
others risk factors, that could inﬂuence the throm-
boembolic event during surgical procedures. None of
the parameters, whether measured before or after
surgery, varied signiﬁcantly from the physiologic
range. The statistical signiﬁcance test (t test) con-
ﬁrmed this data (0.03, 30%). These data suggest that
Table 3. Admission T0 coagulative parameters in female
patients
Mean ± SD
PT (%) 100.02 ± 15.33
aPTT (sec) 31.44 ± 3.80
FIBR (mg/dl) 361.10 ± 125.38
ATIII (%) 98.90 ± 2.45
PC (%) 103.0 ± 20.74
PT, prothrombin time; aPTT, activated partial thrombo-
plastin time; FIBR, ﬁbrinogen; ATIII, antithrombin III;
PC, protein C
Table 2. Admission T0 coagulative parameters in male
patients
Mean ± SD
PT (%) 104.31 ± 12.05
aPTT (sec) 28.49 ± 3.68
FIBR (mg/dl) 340.56 ± 103.25
ATIII (%) 110.66 ± 20.40
PC (%) 135.57 ± 28.68
PT, prothrombin time; aPTT, activated partial thrombo-
plastin time; FIBR, ﬁbrinogen; ATIII, antithrombin III;
PC, protein C
Table 4. Postoperative (T7) coagulative parameters in male
patients
Median
PT (%) 97.46 ± 8.05
aPTT (sec) 25.00 ± 9.94
FIBR (mg/dl) 305.00 ± 64.90
ATIII (%) 101.25 ± 3.68
PC (%) 117.77 ± 24.09
PT, prothrombin time; aPTT, activated partial thrombo-
plastin time; FIBR, ﬁbrinogen; ATIII, antithrombin III;
PC, protein C
Table 5. Postoperative (T7) coagulative parameters in fe-
male patients
Median
PT (%) 104.30 ± 16.09
aPTT (sec) 30.30 ± 4.41
FIBR (mg/dl) 411.10 ± 127.07
ATIII (%) 101.38 ± 2.35
PC (%) 125.65 ± 14.31
PT, prothrombin time; aPTT, activated partial thrombo-
plastin time; FIBR, ﬁbrinogen; ATIII, antithrombin III;
PC, protein Ccorrect?
Table 6. Comparison of Pre- and Postoperative Results
(t0/t7)
Male Patientsa
PT (%) Slightly decreased
aPTT (sec) Slightly decreased
FIBR (mg/dl) Moderately decreased
ATIII (%) Slightly decreased
PC(%) Slightly decreased
Female Patientsb
PT (%) Slightly decreased
aPTT (sec) Slightly decreased
FIBR (mg/dl) Moderately increased
ATIII (%) Slightly increased
PC (%) Moderately increased
aEvaluation of examined results in male patients (t0/t7)
bEvaluation of examined results in female patient (t0/t7)
PT, prothrombin time; aPTT, activated partial thrombo-
plastin time; FIBR, ﬁbrinogen; ATIII, antithrombin III;
PC, protein C
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during the postoperative period, women have a lower
risk of hypercoagulative (thromboembolic) compli-
cations.
To the best of our knowledge, other studies have
not addressed such issues in plastic surgery, although
there are many studies pertaining to other surgical
specializations such as gynecology, maxillofacial
surgery, abdominal surgery, and heart surgery
[1,2,8,9,11,16,21,26]. In other works, physiologic an-
tithrombotic (PC and ATIII) pre- and postoperative
levels were discordant. A similar trend was observed
in a group of abdominal surgery patients, with a
maximum decrease of PC and ATIII recorded 2 days
after surgery [16,29]. However, our study is not
suitable for comparative purposes because of the
insigniﬁcant statistical test (t test).
With regard to other parameters (PT, aPTT,
ﬁbrinogen) in the literature, the results from pre- and
postsurgical monitoring were in accordance. Pro-
thrombin time and aPTT showed no evidence of any
change, but there was a moderate increase in ﬁbrin-
ogen. Our study demonstrated a statically important
trend only with ﬁbrinogen [3].
Conclusions
Analysis of the results suggests that immediately after
surgery, in the absence of any preexisting hypo- or
hypercoagulability state, there was no circumstantial
modiﬁcation in coagulation factors considered sug-
gestive of thromboembolic risk. However, an inter-
esting diﬀerence between male and female patients
was found. In the male group, there was an unim-
portant uniform downward trend of all values
immediately after surgery. In the female group, in-
stead, there was a global upward trend (except for
aPTT). Interestingly, the PC and ATIII results were
statically signiﬁcant. In conclusion, females are less
hypercoagulative postoperatively, suggesting that fe-
males may have slight protection from the develop-
ment of thromboembolic complications immediately
after surgical procedures.
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